Abstract
p21-activated kinase 2 (PAK2) is a critical serine/threonine protein kinase whose role in lung squamous cell carcinoma (LUSC) progression has remained largely elusive. This study demonstrates that PAK2 is significantly upregulated in human LUSC tissues at the mRNA, DNA copy number, and protein levels. High PAK2 expression correlates with poor patient prognosis. Functional assays reveal that PAK2 drives cell growth, migration, invasion, and epithelial-mesenchymal transition (EMT). Mechanistically, PAK2 regulates actin dynamics via the LIMK1/cofilin signaling pathway, identifying it as a potential clinical marker and therapeutic target for LUSC.
Introduction
Lung cancer is a leading cause of cancer-related mortality worldwide. Lung squamous cell carcinoma (LUSC), a major subtype of non-small cell lung cancer (NSCLC), is characterized by its aggressive nature and a lack of effective targeted therapies compared to adenocarcinoma. While the p21-activated kinase (PAK) family is known to influence various cancers, the specific role of PAK2 in LUSC progression required further investigation. This research aimed to evaluate PAK2 as a prognostic marker and elucidate the molecular mechanisms by which it promotes tumor advancement.
Methods
The study utilized a comprehensive experimental design:
- Clinical Analysis: mRNA and protein expression were analyzed in 30 LUSC and 24 adenocarcinoma cases, comparing tumor tissues with adjacent normal tissues. Tissue microarrays (TMAs) were used to correlate PAK2 levels with clinical outcomes.
- Functional Assays: LUSC cell lines (H226 and H520) were modified using shRNA for knockdown and plasmids for overexpression. Proliferation, migration (wound healing), and invasion (Matrigel) were assessed.
- Molecular Mechanism: Western blotting and immunofluorescence tracked the phosphorylation of LIMK1 and cofilin, alongside changes in F-actin organization.
- In Vivo Studies: PAK2-silenced cells were injected into nude mice to evaluate tumor growth in a physiological environment.
Genomic and Clinical Datasets
The researchers validated their findings using both primary patient samples and public genomic databases:
- Patient Cohort: 54 matched NSCLC and normal tissue samples from Nanjing Chest Hospital.
- Bioinformatics Validation: Data from TCGA, CPTAC, and cBioPortal confirmed PAK2 mRNA expression trends and DNA copy number variations.
Key Insights: The PAK2/LIMK1/Cofilin Axis
- Prognostic Significance: High PAK2 expression is a strong predictor of advanced tumor stage and reduced overall survival (median survival of 54 months vs. 66 months in low-expression groups).
- Actin Cytoskeleton Regulation: PAK2 hijacks the LIMK1/cofilin pathway to control cell motility. Cofilin normally severs actin filaments; however, PAK2-activated LIMK1 phosphorylates cofilin, inhibiting its activity. This stabilizes F-actin, providing the structural force necessary for migration and invasion.
- Induction of EMT: PAK2 facilitates the Epithelial-Mesenchymal Transition (EMT), reducing E-cadherin and increasing N-cadherin and vimentin levels, thereby enhancing the invasive potential of LUSC cells.
Results
- Upregulation in LUSC: PAK2 levels are markedly higher in LUSC tissues than in normal controls.
- Tumor Growth Inhibition: Silencing PAK2 in vivo significantly reduced tumor volume and weight in mouse models.
- Pathway Validation: Overexpression of LIMK1 partially rescued the migration and invasion deficits caused by PAK2 silencing, confirming the central role of the PAK2 → LIMK1 → cofilin signaling highway.
Conclusion and Future Directions
This study identifies PAK2 as a key driver of LUSC progression through the regulation of actin dynamics. While the findings are compelling, future research with larger clinical cohorts is necessary to validate PAK2 as a robust biomarker. Additionally, exploring the therapeutic potential of PAK2 or LIMK1 inhibitors could offer new treatment avenues for LUSC patients who currently lack targeted options.
Summary updated